Project Grant HT94252311029

This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, is funding the development of an innovative portable device to rapidly detect and monitor traumatic brain injury (TBI) biomarkers. The $332,122 award to Hemex Health Inc. aims to create a point-of-care diagnostic platform that can quickly analyze whole blood samples to identify elevated...

This federal Project Grant award for $532,385 from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, supports research to develop a novel targeted nanotherapeutic platform for delivering small molecule drugs across the blood-brain barrier to treat neurological diseases. The grant recipient, Washington State University, is designing and testing a glycodendrimer...

This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Project Grant award provides $274,855 to Mito-Biotherapeutics, Inc. to develop a novel fusion protein construct (NFP) that can cross the blood-brain barrier and deliver a therapeutic payload to repair mitochondrial DNA damage in neurons following traumatic brain injury (TBI). The project aims to attenuate neurological damage and prevent the progression of TBI to neurodegenerative diseases like...

The U.S. Defense Health Agency awarded a $2,550,000 Project Grant to Alcamena Stem Cell Therapeutics, LLC, a small disadvantaged business in Spencerville, MD, to develop a new drug modality to restore cognitive and psychological health after traumatic brain injury. This award is part of the Military Medical Research and Development program (CFDA 12.420), which supports biomedical research initiatives to transform healthcare for military personnel, veterans, and the broader public. Alcamena...

This federal Project Grant award from the National Institute on Aging's Aging Research program (CFDA 93.866) provides $499,441 to Acepre, LLC to develop a novel brain-targeted delivery system for the compound N-acetylcysteine (TN-NAC) as a potential treatment for Alzheimer's disease (AD). The key objectives of this Phase I STTR study are to: 1) evaluate the toxicity and pharmacokinetic properties of TN-NAC in mice, and 2) test the therapeutic efficacy of TN-NAC in a 3xTG-AD mouse model of...

This Project Grant award for $453,860.00 from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, supports research to investigate the metabolic regulation of neutrophil extracellular traps (NETs) in traumatic brain injury (TBI). The research aims to elucidate how AMPK activation protects the brain by reducing NET formation and inflammation following TBI, with the goal...

This $524,243 Project Grant awarded by the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) will support the development of a portable, bedside transcranial magnetic stimulation (TMS) and electroencephalography (EEG) device called "PRESENCE" by Intrinsic Powers, Inc. The device is designed to rapidly and accurately diagnose disorders of consciousness in intensive care...

This federal Project Grant award of $453,970.00 from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program will fund research to determine the effects of intranasal administration of the neurotrophic growth factor heparin-binding epidermal growth factor (HB-EGF) on brain glucose metabolism and inflammation following traumatic brain injury (TBI) in the developing brain. The...

The Defense Health Agency awarded a $1,973,398 Project Grant under the Military Medical Research and Development program (CFDA 12.420) to Azevan Pharmaceuticals Inc. in Bethlehem, PA. The grant supports the development of a new drug to prevent the effects of mild traumatic brain injury (TBI) or concussion. The research project will be conducted over a 2-year period from June 2024 to June 2026. The goal is to advance the development of an innovative medical solution to address this critical...

The Regents of the University of Minnesota received a $391,215 Project Grant from the National Center for Complementary and Integrative Health (CFDA 93.213) to conduct research on "Mechanistic Underpinnings of Trigeminal Nerve Stimulation as a Therapeutic Approach to TBI." The project aims to utilize mouse experiments and numerical simulations to investigate how trigeminal nerve stimulation can reduce cerebral edema and improve functional outcomes in traumatic brain injury (TBI)...